| Ticker: UROQ | 265 East 100 South, Suite 220 | |
| Exchange: NASDAQ-National Market | Salt Lake City, Utah 84111 | |
| Industry: Manufacturing | (801) 322-1554 |
| Type of Shares: | Common Shares | Filing Date: | 6/28/96 | |
| U.S. Shares: | 3,350,000 | Offer Date: | 10/24/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $8.00 - $10.00 | |
| Primary Shares: | 3,350,000 | Offer Price: | $6.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.42 | |
| Offering Amount: | $30,150,000 | Selling: | $0.24 | |
| Expenses: | $500,000 | Reallowance: | $0.10 | |
| Shares Out After: | 11,818,626 |
| Manager | Tier | Phone |
| Dillon, Read & Co. Inc. | Lead Manager | (212) 906-7000 |
| Prudential Securities Incorporated | Co-manager | (212) 214-3000 |
| Auditor: KPMG Peat Marwick | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 6/30/96 | 6/30/95 | 6/30/96 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $27.89 |
| Net Income: | -$1.51 | -$0.82 | -$0.63 | Liabilities: | $14.26 |
| EPS: | -$0.36 | -$0.18 | Equity: | $13.62 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| UroQuest Medical Corporation was formed to design, develop and market advanced products for the management and diagnosis of both male and female urological disorders. The Company's principal product, the On-Command Catheter, is and endourethral catheter incorporating a proprietary anchoring system and proprietary patient controlled, magnetically actuated in-line valves used to regulate urine flow. The On-Command Catheter is deigned to enable persons with either urinary incontinence or urinary retention to manage their condition without the restricted mobility, medical complications, discomfort and embarrassment generally associated with many of the existing management alternatives, including intermittent, Foley, external and suprapubic catheters, diapers and absorbents, and penile clamps. Clinical trials to date have demonstrated the utility of the On-Command Catheter in managing male urinary outflow disorders. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used to fund clinical trials, sales and marketing, the acquisition of BMT, research and development, and for working capital and general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.